Lactoferrin Supplementation Iron Status Randomized Trial: What the Evidence Says

Quick Answer

Lactoferrin Supplementation Iron Status Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 preclinical study, 1 research article.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• These peptides have been associated with immune regulation, anti-inflammatory, and antimicrobial properties, possibly modulating the gut microbiome and exhibiting systemic activity to mitigate microbial infections. [Kaplan Nicole (2026); evidence level 4]
• In a clinical study, lactoferrin supplementation has been linked to a pronounced increase in circulating neutrophil precursors, and an associated reduction in TNF-α and IL-6 production. [Kaplan Nicole (2026); evidence level 4]
• Women with IDWA may still experience fatigue, reduced concentration, impaired physical performance, and lower quality of life, and IDWA is estimated to affect approximately 15%-35% of women. [Muacevic Alexander (2026); evidence level 4]
• Iron supplementation remains the standard treatment for iron deficiency; however, it is associated with many side effects, including gastrointestinal symptoms such as constipation, nausea, and abdominal discomfort. [Muacevic Alexander (2026); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

For lactoferrin supplementation iron status randomized trial, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Kaplan Nicole (2026). The Protective and Regenerative Potential of Lactoferrin in Hair and Skin Health. DOI: 10.3390/ijms27104451. PMCID: PMC13207968. PMID: 42196429. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13207968/
• Muacevic Alexander (2026). Improving Iron Status Without Iron: Clinical Insights From Recombinant Human Lactoferrin Supplementation. DOI: 10.7759/cureus.107451. PMCID: PMC13098296. PMID: 42022247. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13098296/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.